常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.32/-0.30
|
|
企业价值
382.37M
|
| 资产负债 |
|
每股账面净值
2.25
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
-221,563,000
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab. |

3.28 
